Jason Bhardwaj

Jason Bhardwaj currently serves as the CEO of Nova Anchora, a biopharmaceutical company focused on developing a protein therapy for epidermolysis bullosa, leveraging technology and intellectual property licensed from Stanford University. Prior to this role, Jason was the CEO of Follica, Inc., where innovative treatments for androgenetic alopecia were developed through the stimulation of new hair follicle growth. Jason's career also includes serving as VP, Commercial at Tal Medical Inc., where the focus was on neuromodulation therapy for depression, and as an Executive at Wellist, a health tech company providing support services for patients and caregivers. Jason's earlier experience spans strategy consulting at Bain & Company, and marketing at Medtronic within the Cardiac Rhythm Disease Management division. Educational credentials include a Bachelor's Degree in Biomedical Engineering and Economics from Duke University and an MBA from Harvard Business School.